Clinical and Developmental Immunology
Volume 2010, Article ID 473453, 11 pages
http://dx.doi.org/10.1155/2010/473453
Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
1Section of Hematology and Oncology, Department of Medicine, College of Medicine Research Building, University of Illinois at Chicago, 909 South Wolcott Avenue, Chicago, IL 60612, USA
2Department of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA
3Proteomics Core Research Facility, Rush University Medical Center, Chicago, IL 60612, USA
Received 1 July 2010; Revised 7 December 2010; Accepted 14 December 2010
Academic Editor: Bartholomew Akanmori
Copyright © 2010 Supriya Perambakam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to Cite this Article
Supriya Perambakam, Hui Xie, Seby Edassery, and David J. Peace, “Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154),” Clinical and Developmental Immunology, vol. 2010, Article ID 473453, 11 pages, 2010. https://doi.org/10.1155/2010/473453.